Leading Development of Novel Anti-Infective Products in the Era of Increasing Bacterial Resistance

August 2017
This presentation contains certain statements that constitute forward-looking statements within the meaning of the federal securities laws. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. The forward looking statements in this presentation include statements about our business, including commercialization plans and potential markets for our products and product candidates, clinical trials, potential indications for our product candidates, development timelines, regulatory timelines and future events that have not yet occurred. Pharmaceutical and medical device development inherently involves significant risks and uncertainties, including the risks outlined in “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission and in “Risk Factors” in our Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Our actual results may differ materially from our expectations due to these risks and uncertainties, including, but not limited to, our dependence on the success of our lead product candidate Neutrolin, and factors relating to commercialization and regulatory approval thereof; unpredictability of the size of the markets for, and market acceptance of Neutrolin; the cost, timing and results of the ongoing and planned Phase 3 trials for Neutrolin in the U.S.; our need for and ability to raise sufficient capital; our ability to identify and enter into strategic transactions; intellectual property protection; retaining our stock’s listing on the NYSE MKT; research and development activities; competition; industry environment, and other matters. Any forward-looking statements included in this presentation are based on information available to us on the date of this presentation. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Mission Statement

To harness its taurolidine technology for the prevention and treatment of infectious, inflammatory, and other serious diseases

First commercial product candidate: Neutrolin®
A novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters

Proprietary formulation of taurolidine, heparin and citrate
Summary and Value Proposition

- U.S. FDA Fast-track status with Phase 3 hemodialysis trial underway
  - Proven clinical utility in EU post-market observational study

- Granted QIDP Designation – up to 10.5 years potential market exclusivity in U.S.

- Additional value may be unlocked through leveraging the platform
  - Taurolidine use in oncology and medical device applications
  - Research collaborations in place and multiple discussions ongoing

- Additional pivotal and post-market studies planned to expand Neutrolin use

- Neutrolin currently available in EU and Middle East (CE Marked)
## Corporate Overview

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Founded</strong></td>
<td>January 2006</td>
</tr>
<tr>
<td><strong>Exchange: Ticker</strong></td>
<td>NYSEMKT: CRMD</td>
</tr>
<tr>
<td><strong>Headquarters</strong></td>
<td>Bedminster, NJ</td>
</tr>
<tr>
<td><strong>Employees</strong></td>
<td>14</td>
</tr>
<tr>
<td><strong>Shares Outstanding</strong></td>
<td>59.3 Million (May 30, 2017)</td>
</tr>
<tr>
<td><strong>Warrants Outstanding</strong></td>
<td>33.1 Million</td>
</tr>
<tr>
<td><strong>Cash</strong></td>
<td>$13.8 million* (March 31, 2017)</td>
</tr>
<tr>
<td></td>
<td>*Raised $12.9 million (April 2017)</td>
</tr>
<tr>
<td><strong>Debt</strong></td>
<td>$0</td>
</tr>
<tr>
<td><strong>Share Price [05/30/2017]</strong></td>
<td>$0.41</td>
</tr>
<tr>
<td><strong>Market Cap [05/30/2017]</strong></td>
<td>$24.0 million</td>
</tr>
</tbody>
</table>
Neutrolin®: Non-antibiotic Anti-Infective to Prevent CRBSI

**Key Benefits:**

- Prevents and reduces bloodstream infection
  - Bacteria and fungi
  - Antibiotic-resistant strains
  - No reported resistance in a clinical setting

- Inhibits peptide crosslinking in microbial cell walls

- Prevents microbial colonization and biofilm formation inside catheter

- Neutralizes endotoxins, exotoxins and lipopolysaccharides released by bacteria

- Reduces thrombosis; Optimizes catheter patency and reduces expensive catheter complications
Neutrolin® is Designed to Protect Patients and Hospitals

The Problem

• Catheter-related blood stream infections (CRBSI)
• Cause extensive morbidity and mortality
• Prolong hospital stays
• Antibiotic resistance a growing concern

CRBSIs are dangerous and costly
• 250,000 CRBSIs in U.S. annually
• 12-25% mortality rate
• Cost = up to $56,000 per infection

Our Solution

Neutrolin® - Proprietary anti-infective solution
• Maintains catheter patency by:
  – Significantly decreasing CRBSIs
  – Decreasing (preventing) blood clots

Impact for hemodialysis and oncology patients
• Phase 3 program underway

# Current Taurolidine-Based Pipeline

## Drug Pipeline:

<table>
<thead>
<tr>
<th>Product Category</th>
<th>Indication</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Marketed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutrolin® U.S.</td>
<td>Hemodialysis</td>
<td>Currently Enrolling</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oncology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ICU / CCU</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRMD-005 / Vincristine Combo NanoParticle</td>
<td>Pediatric Neuroblastoma*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Orphan Disease Opportunity

## Device Pipeline:

<table>
<thead>
<tr>
<th>Product Category</th>
<th>Indication(s)</th>
<th>Preclinical</th>
<th>In Vitro PoC</th>
<th>In Vivo PoC</th>
<th>510(k)**</th>
<th>Marketed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutrolin® Europe</td>
<td>Catheter lock solution</td>
<td>CE Marked</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taurolidine-Incorporated:</td>
<td>Wound closure/surgery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Burns/diabetic foot ulcer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Burns and hernia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

** Regulatory pathway dependent on FDA acceptance of predicate devices for each product candidate
Medical Opportunity

Despite improvements and initiatives to control infection, biofilm develops very quickly and can lead to life-threatening complications, costing the U.S. healthcare system billions of dollars annually.

Significant Unmet Need

- 250,000 CRBSIs per year in the U.S.
- Microbial biofilms responsible for majority of CRBSI
- Bacteria are significantly more resistant to antibiotics within a biofilm
- Mortality rate: 12-25%

Neutrolin®: Protecting Chronic Care Patients From Infection

• Large and growing unmet medical need – **increasing number of catheterization** in patients in hemodialysis, oncology, and intensive care units coupled with a **growing anti-microbial resistance**

• **Neutrolin** is an anti-microbial solution, lead product candidate in **Phase 3** clinical development (U.S.) for central venous catheter infection reduction

• **CE Mark already granted** in certain European Union and other territories

• **Neutrolin** Granted FDA Fast Track and Qualified Infectious Disease Product (QIDP) designation to allow for expedited approval process

Neutrolin®: Non-antibiotic Anti-Infective to Prevent CRBSI

Lack of Microbial Resistance:

- Adaptation of microorganisms to taurolidine has not yet emerged as a factor in the pathogenesis of CRBSI
- Bacterial resistance has not been reported, as taurolidine’s mode of action resembles a anti-infective rather than an antibiotic
- Broadly active against bacteria, including antibiotic-resistant MRSA, VISA, VRSA, ORSA and VRE

Spectrum of Coverage:

- Gram positive microorganisms:
  - Coagulase-negative *Staphylococcus* species and *Staphylococcus aureus*
- Gram negative microorganisms:
  - *Klebsiella pneumoniae*, *Escherichia coli* and *Pseudomonas aeruginosa*
- Clinically relevant fungi:
  - *Candida albicans* and *Aspergillus fumigatus*
Focused on Execution of Phase 3 U.S. Clinical Strategy

Approval Pathway: Designated an investigational new drug by FDA
• Granted FDA Fast Track
• Qualified Infectious Disease Product (QIDP)

Phase 3 “LOCK-IT” Program (Catheter LOCK Solution Investigational Trial)
• Ongoing: LOCK-IT 100: Currently enrolling hemodialysis patients
  • Expected Milestones:
    • Q4 2017: Potential interim review
    • Q2 2018: Complete patient enrollment
    • Around year end 2018: Report top-line data

• Planned: LOCK-IT 200: Oncology patients with central venous catheters

Anticipated Post-market Phase 4 studies: ICU/CCU patients
## LOCK-IT 100: Preventing CRBSI in Dialysis Patients

| **Current Study Design** | Phase 3, multicenter, double-blind, randomized (1:1), active control (heparin)  
| | • 632 hemodialysis patients on a catheter for end stage renal disease (ESRD)  
| | • Approx. 70 clinical centers in the U.S.  
| | • *Changes to study protocol currently under discussion with FDA* |

| **Objectives** | Demonstrate the efficacy and safety of Neutrolin® as a catheter lock solution for the prevention of CRBSI and the incidence of treatment-emergent adverse events compared to heparin (1000 u/ml)  
| | • Goal to achieve significant reduction in infection rate vs. heparin |

| **Primary Endpoint** | Time to occurrence of CRBSI |

| **Secondary Endpoints** | • Catheter patency: loss of catheter patency following study enrollment  
| | • Catheter removal: removal of catheter for any reason following study enrollment |
More ESRD Patients = Greater CRBSI Risk

Increased Burden to Healthcare System

Catheter-Related Blood Stream Infections (CRBSI)

~ 55k CRBSI related to ESRD per year

~ 20% of ESRD patients remain on catheters >1st yr

~ 62 million catheter hemodialysis days per yr

Sources:
- Company 10-K; 2016 USRDS Annual Data Report | Volume 2 - ESRD in the United States;

ESRD: End stage renal disease
Neutrolin Clinically Validated in Real World Study

Neutrolin Usage Monitoring Program (NUMP)
Open-label, post-market observational study

- Primary outcome: monitor safety and efficacy of CE Marked Neutrolin in preventing infection and thrombosis
- Positive results consistent with prior clinical studies
  - 202 hemodialysis patients
  - 36,083 catheter days
- Reduces risk in ongoing Phase 3 study
- Data accumulated from NUMP registry add support to NDA

Neutrolin Significantly Reduces Infection and Thrombosis
Rate per 1000 catheter days

1. CDC Guidelines for the Prevention of Intravascular Catheter Related Infections; O’Grady et al., 2011;
Catheter Lock Solutions - U.S. Market Potential is Significant; Driven by Catheter Days

<table>
<thead>
<tr>
<th>Neutrolin®</th>
<th>Patients</th>
<th>Estimated Catheter Days</th>
<th>Vials per Catheter Day</th>
<th>Total Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemodialysis</td>
<td>660,000</td>
<td>63mm</td>
<td>0.5</td>
<td>31mm</td>
</tr>
<tr>
<td>Oncology/TPN</td>
<td>7,740,000</td>
<td>90mm</td>
<td>3</td>
<td>270mm</td>
</tr>
<tr>
<td>ICU</td>
<td>5,700,000</td>
<td>29mm</td>
<td>5</td>
<td>143mm</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>444mm</strong></td>
</tr>
</tbody>
</table>

Catheter Population and Opportunity are Significant

Unlocking Additional Value for Taurolidine

**CRMD-005**

- Proprietary formulation of taurolidine
- Combination with standard chemotherapy agent, delivered by novel nanoparticle technology
- Initially targeting pediatric neuroblastoma (Orphan Disease)

**Medical Devices**

- **Sutures**: protect exposed skin from infection
- **HydroGels**: for burns and diabetes foot ulcers
- **Mesh**: for hernia repair and burns
Novel Taurrolidine-based Cancer Therapy

Data & Mechanism Of Action

- Known to inhibit a variety of human cancer cell growth in vitro\(^1\)
- Enhances activity of cytotoxic drugs against neuroblastoma\(^1,2\)

February 2017: Agreement with Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC)

- Develop and evaluate novel taurrolidine-based therapies for rare orphan pediatric tumors
- Memorial Sloan Kettering Cancer Center (MSK), Weill Cornell Medical Center, Alberta Children’s Hospital, and other top tier cancer centers of excellence

---

# Taurodine’s Anti-infective/Anti-Inflammatory Properties Add Value to Medical Devices

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sutures</td>
<td>$3.9B</td>
<td>$1.7B</td>
<td>All</td>
</tr>
<tr>
<td>Hydrogels</td>
<td>$1.9B</td>
<td>$1.02B</td>
<td>Burns/DFU/Osteoarthritis</td>
</tr>
<tr>
<td>Mesh</td>
<td>$2.0B</td>
<td>$1.0B</td>
<td>Hernia repair/Burns/Wounds/Reconstructive Surgery</td>
</tr>
</tbody>
</table>

1. Sutures: Reference LSI- WW141WO
2. Hydrogels: Reference US Markets for Advanced Wound Care Products, August 2015
3. Mesh: LSI Market Research LSI-WW1518SU
Summary and Value Proposition

• U.S. FDA Fast-track status with Phase 3 hemodialysis trial underway
  • Proven clinical utility in EU post-market observational study

• Granted QIDP Designation – up to 10.5 years potential market exclusivity in U.S.

• Additional value may be unlocked through leveraging the platform
  • Taurolidine use in oncology and medical device applications
  • Research collaborations in place and multiple discussions ongoing

• Additional pivotal and post-market studies planned to expand Neutrolin use

• Neutrolin currently available in EU and Middle East (CE Marked)
Thank You

NYSE MKT: CRMD
1430 Route 206
Suite 200
Bedminster, NJ 07921
908.517.9500
@CorMedixInc

Investor & Media Contacts
Tiberend Strategic Advisors, Inc.

Josh Drumm, Ph.D.
jdrumm@tiberend.com; 212-375-2664

Janine McCargo
jmccargo@tiberend.com; 646-604-5150